- Home
- BNZI vs NLSP Comparison
BNZI vs NLSP Comparison
Compare BNZI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- NLSP
- Stock Information
- Founded
- BNZI 2016
- NLSP 2015
- Country
- BNZI United States
- NLSP Switzerland
- Employees
- BNZI N/A
- NLSP N/A
- Industry
- BNZI
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BNZI
- NLSP Health Care
- Exchange
- BNZI Nasdaq
- NLSP Nasdaq
- Market Cap
- BNZI 11.5M
- NLSP 12.4M
- IPO Year
- BNZI N/A
- NLSP 2021
- Fundamental
- Price
- BNZI $2.46
- NLSP $1.96
- Analyst Decision
- BNZI Strong Buy
- NLSP
- Analyst Count
- BNZI 1
- NLSP 0
- Target Price
- BNZI $240.00
- NLSP N/A
- AVG Volume (30 Days)
- BNZI 402.9K
- NLSP 217.3K
- Earning Date
- BNZI 08-14-2025
- NLSP 10-17-2025
- Dividend Yield
- BNZI N/A
- NLSP N/A
- EPS Growth
- BNZI N/A
- NLSP N/A
- EPS
- BNZI N/A
- NLSP N/A
- Revenue
- BNZI $9,021,543.00
- NLSP N/A
- Revenue This Year
- BNZI $337.60
- NLSP N/A
- Revenue Next Year
- BNZI $91.81
- NLSP N/A
- P/E Ratio
- BNZI N/A
- NLSP N/A
- Revenue Growth
- BNZI 107.94
- NLSP N/A
- 52 Week Low
- BNZI $2.35
- NLSP $1.30
- 52 Week High
- BNZI $112.00
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- BNZI 32.88
- NLSP 39.28
- Support Level
- BNZI $3.06
- NLSP $1.88
- Resistance Level
- BNZI $3.43
- NLSP $2.29
- Average True Range (ATR)
- BNZI 0.29
- NLSP 0.17
- MACD
- BNZI -0.01
- NLSP -0.06
- Stochastic Oscillator
- BNZI 7.19
- NLSP 8.67
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.